Literature DB >> 2110579

Superficial migratory thrombophlebitis and factor XII deficiency.

C P Samlaska1, W D James, D L Simel.   

Abstract

A patient with painful migratory erythematous nodules for 7 years is presented. The nodules, which were localized on the lower and upper extremities, progressed to palpable cords. Multiple venograms showed no evidence of deep vein thrombosis. Skin biopsy specimens were diagnostic of superficial thrombophlebitis. There was no evidence of internal malignancy. Extensive evaluation for an underlying hypercoagulable state was remarkable for a factor XII level 17% of normal. The patient was unresponsive to a wide range of treatments. The recalcitrant nature of his disease and lack of deep venous involvement are unique. An underlying hypercoagulable state should be considered when the diagnosis of superficial migratory thrombophlebitis is considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110579     DOI: 10.1016/0190-9622(90)70130-a

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Behçet's syndrome and factor XII deficiency.

Authors:  P Disdier; J R Harle; A Mouly; M F Aillaud; P J Weiller
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

2.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 3.  [Superficial venous thrombosis. A review].

Authors:  C Jeanneret; S Brunner
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

Review 4.  The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

Authors:  A Girolami; M L Randi; S Gavasso; A M Lombardi; F Spiezia
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.